• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Elevated Blood Inflammatory Marker Linked to Extended Window Tenecteplase Stroke Benefit

by
November 20, 2026
in Health
Reading Time: 6 mins read
0
Elevated Blood Inflammatory Marker Linked to Extended Window Tenecteplase Stroke Benefit

Elevated Blood Inflammatory Marker Linked to Extended Window Tenecteplase Stroke Benefit

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Patients presenting with acute ischemic stroke caused by large vessel occlusion between 4.5 and 24 hours after symptom onset experienced improved 90-day functional independence following intravenous tenecteplase treatment if they had an elevated baseline neutrophil to lymphocyte ratio, according to an exploratory post hoc analysis of the randomized TRACE-III clinical trial. Researchers observed that among individuals exhibiting an admission neutrophil to lymphocyte ratio exceeding 3.0, treatment with intravenous tenecteplase resulted in an adjusted relative rate of 1.51 for achieving an excellent functional outcome, defined as a modified Rankin scale score of 0 or 1 at three months, compared with standard medical therapy alone. This statistically significant clinical divergence was not detected among individuals whose baseline inflammatory ratios fell at or below that threshold, where the adjusted relative rate was 1.12 with confidence intervals crossing unity. The findings suggest that admission systemic inflammatory status may correlate with a differential clinical response to delayed thrombolytic reperfusion, offering initial evidence that circulating immune profiles could help identify patients who retain salvageable neurological function in later therapeutic windows.

Intravenous thrombolysis and endovascular thrombectomy represent the primary interventions for restoring blood flow following acute ischemic stroke, with endovascular procedures strongly recommended by clinical guidelines for patients harboring large vessel occlusions in the cerebral circulation. In routine clinical practice, however, access to mechanical thrombectomy is severely constrained across global healthcare settings, displaying an estimated international median availability rate of only 2.79 percent. Although established thrombolytic regimens utilizing alteplase or newer third-generation thrombolytics like tenecteplase demonstrate clinical efficacy when administered within 4.5 hours of symptom onset, epidemiological data indicate that more than 70 percent of stroke patients arrive at hospital emergency facilities beyond this initial 4.5-hour timeframe or present with an unknown onset time, such as wake-up strokes. Consequently, medical researchers have sought to clarify whether delayed pharmacological reperfusion can safely benefit selected individuals who are unable to receive catheter-based endovascular thrombectomy, establishing a critical need to understand which patient subgroups demonstrate meaningful recovery when treated many hours after initial vascular occlusion.

Severe secondary complications following ischemic stroke, including symptomatic intracranial hemorrhage, cerebral edema, and early neurological deterioration, are primary drivers of poor functional outcomes after reperfusion therapy and are closely linked to heightened systemic inflammation. The neutrophil to lymphocyte ratio has emerged as a readily accessible prognostic biomarker that clinicians can obtain directly from routine automated complete blood cell counts upon patient admission. Prior research has identified higher ratios as an independent predictor of symptomatic intracranial hemorrhage, progressive neurological decline, and 90-day mortality among patients undergoing reperfusion for large vessel occlusions. Furthermore, patients with polyvascular atherothrombotic disease display elevated rates of recurrent vascular events and stronger relationships between systemic inflammatory indices and subsequent outcomes, underscoring the tight physiological connection between circulating immune responses and underlying vascular damage. Systematic reviews and meta-analyses have reinforced that elevated baseline inflammatory ratios frequently accompany unfavorable prognostic trajectories across both mechanical and pharmacological reperfusion settings.

The underlying Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III trial was designed as a phase 3, multicenter, prospective, randomized, open-label, blinded-endpoint trial conducted across 58 medical centers in China between January 2022 and November 2023. The trial enrolled 516 adult participants who presented between 4.5 and 24 hours after symptom onset or from the time they were last known to be well, including unwitnessed presentations and wake-up strokes. All enrolled individuals had moderate to severe neurological deficits, indicated by a baseline National Institutes of Health Stroke Scale score between 6 and 25, an identified occlusion in the anterior cerebral circulation, and definitive evidence of salvageable brain tissue identified by core-perfusion mismatch on advanced perfusion neuroimaging. Because participants could not access mechanical thrombectomy, they were randomly allocated in an equal one-to-one ratio to receive either intravenous tenecteplase or standard medical treatment, with the parent trial demonstrating reduced overall disability without increased risks of mortality or symptomatic intracranial hemorrhage.

To evaluate whether systemic inflammatory status modulated clinical responses during this extended treatment window, investigators conducted a post hoc analysis focusing on 513 trial participants who possessed complete baseline neutrophil to lymphocyte ratio data obtained from admission laboratory draws. Venous blood samples taken during initial emergency evaluation were processed in accordance with local laboratory protocols, calculating the marker as total neutrophil count divided by total lymphocyte count. The researchers established a threshold value of 3.0, representing the cohort’s first quartile, to categorize patients into an elevated ratio group comprising 386 individuals and a non-elevated ratio group of 127 individuals. The overall patient cohort exhibited a median admission ratio of 4.8, with an interquartile range spanning from 3.0 to 7.3. Selecting the first quartile boundary aligned the analytic cutoff with median inflammatory levels previously documented in acute stroke cohorts presenting within standard early windows without advanced imaging requirements, providing a methodological baseline to evaluate differential outcomes.

The evaluation of primary efficacy outcomes revealed that 30.2 percent of patients in the tenecteplase group with an elevated inflammatory ratio achieved an excellent functional outcome at 90 days, compared with 19.6 percent in the standard medical treatment arm. After multivariable log-binomial regression models adjusted for symptom-to-treatment time, baseline smoking status, and specific occlusion locations, this difference yielded an adjusted relative rate of 1.51 with a 95 percent confidence interval of 1.05 to 2.17, reaching statistical significance at a p-value of 0.03. In contrast, among participants within the non-elevated inflammatory cohort, 41.9 percent of those receiving tenecteplase achieved modified Rankin scale scores of 0 or 1, compared with 38.5 percent receiving standard medical care, corresponding to an adjusted relative rate of 1.12 with a 95 percent confidence interval of 0.73 to 1.73. The absolute risk difference for achieving the primary outcome between treatment and control reached 10.6 percentage points in the elevated inflammatory group, whereas the absolute difference was only 3.4 percentage points among non-elevated participants.

Secondary functional and radiographic endpoints demonstrated consistent therapeutic advantages for tenecteplase administration within the elevated inflammatory cohort. Favorable functional independence at 90 days, defined as a modified Rankin scale score of 0 to 2, occurred in 40.1 percent of tenecteplase-treated patients compared with 28.3 percent of medically managed controls, generating an adjusted relative rate of 1.38 with a 95 percent confidence interval between 1.03 and 1.84 and a p-value of 0.03. Furthermore, participants with elevated inflammatory ratios assigned to tenecteplase experienced significantly greater rates of major neurological improvement at 72 hours, defined as an NIHSS reduction of at least 8 points or reaching a score of 0 to 1, alongside significant improvements in 7-day neurological scores. Radiographic evaluations performed 24 hours after intervention showed higher rates of arterial recanalization on the Arterial Occlusive Lesion scale and substantial reperfusion, defined as greater than 90 percent reduction in hypoperfusion volume on follow-up imaging, whereas no significant differences were observed across secondary endpoints in the non-elevated ratio cohort.

Safety analyses indicated that administration of tenecteplase in this extended therapeutic window did not lead to statistically significant increases in serious adverse outcomes, regardless of baseline inflammatory categorization. Symptomatic intracranial hemorrhage within 36 hours post-treatment, assessed according to European Cooperative Acute Stroke Study III diagnostic criteria, occurred in 4.0 percent of tenecteplase patients within the elevated ratio subgroup while none occurred in the non-elevated subgroup, showing no significant divergence from control arms. Similarly, all-cause mortality assessed at 90 days reached 14.9 percent among tenecteplase recipients with elevated ratios compared with 8.1 percent in those with lower ratios, without statistically significant differences between randomized therapies within either stratum. While biological mechanisms involving elevated inflammatory states theoretically heighten microvascular fragility, the study demonstrated that tenecteplase did not disproportionately trigger fatal complications or cerebral bleeding events relative to conservative medical management in these imaging-selected participants.

The biological mechanisms connecting systemic inflammation to stroke outcomes involve complex cellular immune dynamics that unfold rapidly following vascular occlusion. Elevated neutrophil to lymphocyte ratios capture both acute innate immune activation, characterized by expanding neutrophil counts, and concurrent lymphopenia reflecting stress-induced immunosuppression. Neutrophils peak within ischemic cerebral tissue within 24 to 48 hours after injury, releasing reactive oxygen species, matrix metalloproteinase-9, and neutrophil extracellular traps that degrade extracellular matrix and disrupt the blood-brain barrier. Extracellular traps can also modify fibrin architecture, stimulate platelet aggregation, and induce localized resistance to fibrinolysis. Conversely, circulating lymphocytes, particularly protective T-cell populations, undergo functional suppression and depletion within 24 hours of stroke onset due to severe systemic stress responses. Investigators hypothesize that patients experiencing heightened inflammatory cascades face accelerated tissue destruction and higher baseline vulnerability, thereby possessing greater biological potential for clinical salvage when pharmacologically mediated vessel recanalization and tissue reperfusion are successfully achieved.

Despite the observed clinical and radiological correlations, the study investigators highlighted several methodological limitations that necessitate cautious interpretation. Although stratified analyses showed marked improvements within the elevated inflammatory group, formal testing for statistical interaction between treatment assignment and inflammatory categorization produced a non-significant p-value of 0.29, which may reflect limited statistical power from subgroup sample sizes rather than a true absence of biological interaction. Furthermore, categorizing the cohort using the first quartile boundary created an inherent numeric imbalance between the resulting subgroups, while enrolling patients across a wide window from 4.5 to 24 hours introduced temporal variations during which circulating inflammatory markers naturally fluctuate. Because the TRACE-III trial enrolled exclusively Chinese patients, the generalizability of these post hoc observations across diverse demographic populations remains uncertain. The authors concluded that while baseline inflammatory ratios may signal differential recovery following delayed tenecteplase administration, these exploratory findings require rigorous validation in prospective, independent clinical investigations.

Subject of Research: Association between baseline neutrophil to lymphocyte ratio and tenecteplase treatment response in extended-window acute ischemic stroke

Article Title: Neutrophil to Lymphocyte Ratio and Neurological Outcome in Ischemic Stroke at 4.5 to 24 Hours: A Post Hoc Analysis of TRACE-III Trial

Article References: Hao, M., Ma, Y., Wang, L., Jin, A., Law, Z. K., Campbell, B. C. V., Schwamm, L. H., Parsons, M. W., Fisher, M., Xu, Y., Xu, A., Cao, Z., Wang, L., Wu, S., Wang, Y., & Xiong, Y. (2026). Neutrophil to Lymphocyte Ratio and Neurological Outcome in Ischemic Stroke at 4.5 to 24 Hours: A Post Hoc Analysis of TRACE-III Trial. Neurology and Therapy, 15(6), 3491-3505. https://doi.org/10.1007/s40120-026-01060-5

Image Credits: AI Generated

DOI: 10.1007/s40120-026-01060-5

Keywords: acute ischemic stroke, neutrophil to lymphocyte ratio, tenecteplase, TRACE-III trial, thrombolysis, reperfusion therapy, large vessel occlusion, modified Rankin scale, systemic inflammation, symptomatic intracranial hemorrhage, perfusion imaging, extended time window, recanalization, neurological recovery, biomarkers, cerebrovascular disease, innate immunity, clinical neurology

News Source: Cassandra Pierce. (November 20, 2026). Elevated Blood Inflammatory Marker Linked to Extended Window Tenecteplase Stroke Benefit. Scienmag.

Tags: acute ischemic strokebiomarkerscerebrovascular diseaseclinical neurologyextended time windowInnate immunitylarge-vessel occlusionmodified Rankin Scaleneurological recoveryNeutrophil-to-lymphocyte ratioperfusion imagingrecanalizationreperfusion therapysymptomatic intracranial hemorrhageSystemic inflammationtenecteplasethrombolysisTRACE-III trial
Share12Tweet7Share2ShareShareShare1

Related Posts

Purpose-Led Framework Distinguishes Smart Health Homes From General Automation Systems

Purpose-Led Framework Distinguishes Smart Health Homes From General Automation Systems

November 20, 2026
Study Identifies Hypervirulent Klebsiella pneumoniae Predictors in Hospital Bloodstream Infections

Study Identifies Hypervirulent Klebsiella pneumoniae Predictors in Hospital Bloodstream Infections

November 20, 2026

Surgical Patients in Ghana Face Routine Preoperative Procedures Without Adequate Information

November 20, 2026

Audit Identifies Limitations in Head and Neck Cancer Efferocytosis Gene Scores

November 20, 2026

POPULAR NEWS

  • Biased Bubble Chain Navigation Helps Indoor Mobile Robots Accommodate Approaching Pedestrians

    Biased Bubble Chain Navigation Helps Indoor Mobile Robots Accommodate Approaching Pedestrians

    29 shares
    Share 12 Tweet 7
  • Thermophilic Fungus Engineered for High-Yield Bacterial Dipeptidyl Peptidase 4 Secretion

    29 shares
    Share 12 Tweet 7
  • Anterior Talar Osteotomy Corrects Equinus Deformity While Preserving Joint Congruence

    29 shares
    Share 12 Tweet 7
  • Biosensor Mouse Shows Mammary Defects Reversed by Estrogen and Genetic Crossing

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Purpose-Led Framework Distinguishes Smart Health Homes From General Automation Systems

Study Identifies Hypervirulent Klebsiella pneumoniae Predictors in Hospital Bloodstream Infections

Blueberry Byproduct Pigments Effectively Color Clean-Label Cherries Across Storage Testing

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.